ORIGINAL RESEARCH article
Front. Med.
Sec. Nephrology
The Impact of Short-term Administration of Dapagliflozin on Contrast-induced Acute Kidney Injury in Patients with Type 2 Diabetes and Renal Insufficiency Undergoing Percutaneous Coronary Intervention
Provisionally accepted
- 1Tianjin University Chest Hospital, Tianjin, China
- 2Clinical School of Thoracic,Tianjin Medical University, Tianjin, China, Tianjin, China
- 3Tianjin Rehabilitation and Recuperation Center, Joint Logistics Support Force, Tianjin, China
- 4Clinical Medical College of Tianjin Medical University, Tianjin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To investigate the impact of short-term (<2 weeks) administration of dapagliflozin on CIAKI in patients with T2DM and renal insufficiency undergoing PCI. Methods:This retrospective study included patients with T2DM and renal insufficiency who underwent PCI in our hospital, from january to december 2024. The patients were divided into a short-term dapagliflozin group and a control group. Renal function was recorded before PCI, as well as at 48 hours and 1 week post-PCI. The primary endpoint was the incidence of CIAKI after PCI in both groups. The secondary endpoints included changes in renal function at 48 hours and 1 week post-PCI, as well as the occurrence of major adverse cardiovascular events (MACE) during the 3-month follow-up. Results:(1) A total of 354 patients with T2DM and renal insufficiency underwent PCI were included in this study, with 183 patients in the short-term dapagliflozin group and 171 patients in the control group. The median duration of short-term dapagliflozin administration before PCI was 3 (2, 6) days, with an average duration of 3.56 ± 1.62 days. (2) The incidence of CIAKI was higher in the short-term dapagliflozin group (14.2%) compared to the control group (7.0%) (χ2 = 4.769, P=0.029). Logistic regression analysis indicated that short-term dapagliflozin administration before PCI was associated with an increased risk of CIAKI (OR=2.308, 95%CI:1.002–5.314, P=0.049).(3) During the 3-month follow-up after PCI, Log-rank test showed no significant difference in the incidence of MACE between the two groups (Log-rank χ2=0.851, P=0.356).(4) Cox regression analysis revealed that CIAKI significantly affected the short-term prognosis of T2DM patients with renal insufficiency after PCI (HR =3.025, 95%CI:1.246–7.343, P=0.014), whereas dapagliflozin did not significantly improve the short-term prognosis of these patients after PCI (HR=1.024, 95% CI:0.967–1.084, P=0.415). Conclusion: Short-term (<2 weeks) dapagliflozin administration may increase the risk of CIAKI in T2DM patients with renal insufficiency undergoing PCI. It is recommended to avoid initiating dapagliflozin in high-risk CIAKI patients prior to PCI.
Keywords: Contrast-induced acute kidney injury, Coronary Artery Disease, dapagliflozin, Percutaneous Coronary Intervention, Renal Insufficiency, Sodium-glucose cotransporter-2 inhibitors, type 2 diabetes
Received: 12 Nov 2025; Accepted: 02 Dec 2025.
Copyright: © 2025 Yang, Zhu, Zhai, Liu, Zhang and Fu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shicheng Yang
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.